RVPH.US Reviva Pharmaceuticals Holdings Inc.

Healthcare Biotechnology USA Stocks
0.3550 USD
Close of Nov 18, 2026
0.2620 15.40
Market cap
USD 4.65M
P/E
-
P/B
0.35x
ROE
-48.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RVPH.US undervalued?

Graham number

The Graham number of Reviva Pharmaceuticals Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Reviva Pharmaceuticals Holdings Inc. fundamental analysis

No fundamental analysis for Reviva Pharmaceuticals Holdings Inc. yet.

Reviva Pharmaceuticals Holdings Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-def…

Full company profile